Clinical Trials Logo

Influenza, Human clinical trials

View clinical trials related to Influenza, Human.

Filter by:

NCT ID: NCT03651544 Completed - Influenza A Clinical Trials

The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

Start date: October 15, 2018
Phase: Phase 1
Study type: Interventional

The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups with dose escalation.

NCT ID: NCT03637036 Completed - Clinical trials for Influenza Vaccination

An Improvement Project Around Staffs' Influenza Vaccine Uptake

Start date: September 24, 2018
Phase: N/A
Study type: Interventional

To reach seasonal vaccination against influenza targets, University Hospitals Birmingham (UHB) already invites staff to take up the vaccination, and every November reminds staff that have not yet vaccinated to do so. The current protocol describes a randomized controlled trial (RCT) in which staff will be sent different reminders, and the investigators will compare the proportion of staff that go on to vaccinate after receiving each reminder.

NCT ID: NCT03629184 Completed - Influenza Clinical Trials

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Start date: November 20, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.

NCT ID: NCT03617523 Completed - Influenza Clinical Trials

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

GRC90
Start date: September 10, 2018
Phase: Phase 4
Study type: Interventional

The primary objectives of this study were: - To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (<) 36 months of age and 3 to <9 years of age, and in adults 18 to <65 years of age; the immunogenicity of the 2018-2019 formulation of Flublok® Quadrivalent vaccine in adults 18 to <65 years of age; and the immunogenicity of the 2018-2019 formulation of Fluzone High-Dose vaccine in adults greater than or equal to (>=) 65 years of age. - To describe the safety of the 2018-2019 formulation of Fluzone Quadrivalent vaccine in children 6 to <36 months of age and 3 to <9 years of age, and in adults 18 to <65 years of age; the safety of the 2018-2019 formulation of Flublok Quadrivalent vaccine in adults 18 to <65 years of age; and the safety of the 2018-2019 formulation of Fluzone High-Dose vaccine in adults >=65 years of age.

NCT ID: NCT03614975 Completed - Influenza, Human Clinical Trials

Immunologic Response to Influenza Vaccination in Children and Adolescents

Start date: September 13, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-20 years of age. This is a randomized controlled trial (RCT), that will assess immune response in 120 participants (60 per vaccine arm) pre- and post-vaccination to Flucelvax (egg-free inactivated flu shot) and Fluzone (egg-based inactivated flu shot).

NCT ID: NCT03603509 Completed - Influenza Clinical Trials

Gene Signatures of Influenza Vaccine Responses in Older Adults

Start date: August 27, 2018
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and women. The ultimate goal is to understand how flu immunity develops after vaccination. This information may lead to the development of more effective flu vaccines in the future.

NCT ID: NCT03600428 Completed - Asthma Clinical Trials

Safety of LAIV4 in Children With Asthma

Start date: October 15, 2018
Phase: Phase 4
Study type: Interventional

This is a prospective randomized, open label clinical trial in approximately 300 children aged 5-11 years with a physician diagnosis of persistent asthma. Participants will be randomized 1:1 to receive either a single intranasal dose of licensed quadrivalent LAIV (LAIV4) or an intramuscular injection of quadrivalent IIV4 (IIV4).

NCT ID: NCT03599739 Completed - Influenza Clinical Trials

Adjuvanted Influenza Vaccination Year 2 Follow-On Survey

Start date: July 13, 2018
Phase:
Study type: Observational

The purpose of this study is to determine if different influenza vaccines produce different outcomes in nursing facility residents receiving the required annual influenza vaccination.

NCT ID: NCT03594890 Completed - Influenza Clinical Trials

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Start date: June 12, 2018
Phase: Phase 1
Study type: Interventional

The present study is a first-in-man clinical trial evaluating OVX836, a recombinant broad spectrum vaccine for Influenza. This clinical trial will evaluate the safety and the immune response of increasing doses of OVX836 after intramuscular or intranasal administrations in healthy volunteers.

NCT ID: NCT03590808 Completed - Influenza Clinical Trials

Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitor

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to elucidate efficacy and safety of influenza vaccine in cancer patients receiving immune checkpoint inhibitor.